Drug Profile
Research programme: viral nuclear importation inhibitors - Ferring Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cytokine PharmaSciences
- Class Small molecules
- Mechanism of Action Nuclear importation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
- 20 Oct 2011 Cytokine PharmaSciences has been acquired by Ferring Pharmaceuticals
- 01 Jun 2010 The small molecule viral nuclear importation inhibitors are available for licensing (http://www.cytokinepharmasciences.com/next-nuclear-importation-inhibitors.shtml)